In a report released on November 1, Troy Jensen from Cantor Fitzgerald maintained a Buy rating on Proto Labs (PRLB – Research Report), ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 62.43% ...
In a report released today, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on MiMedx Group (MDXG – Research Report), with a ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...
Cantor Fitzgerald raised the firm’s price target on MicroStrategy (MSTR) to $312 from $200 and keeps an Overweight rating on the shares. MicroStrategy, whose core business is being a business ...
Cantor Fitzgerald and Silverstein Properties have topped off Shorehaven, the first phase of South Pier, a $1.8 billion mixed-use development on Tempe Town Lake in Tempe, Ariz. The master-planned ...
Cantor Fitzgerald came out and argued on Monday morning that short-term market bullishness should hold especially with a stimulus coming from the upcoming U.S. presidential election, but bigger ...
Cantor Equity Partners I, a special purpose acquisition company affiliated with Cantor Fitzgerald, filed for a $200 million initial public offering. Howard Lutnick, chairman and chief executive ...
https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-price-target-raised-to-20-from-16-at-piper-sandler Cantor Fitzgerald raised the firm’s price target on ...
Cantor Fitzgerald recently raised the price target on the stock to $225 from $200 and kept an Overweight rating on the shares into Q3 earnings season. The investment firm sees a tale of two ...
Tuesday, Cantor Fitzgerald initiated coverage on Hive Digital Technologies (NASDAQ:HIVE) shares with an Overweight rating and a 12-month price target of $9.00. The firm highlighted HIVE's status ...
On Monday, Cantor Fitzgerald maintained a positive stance on shares of HCA Healthcare Inc (NYSE: NYSE:HCA), raising the price target to $405 from the previous target of $392, while keeping an ...